Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.

Respirology (Carlton, Vic.) - 1 Nov 2006

Kato Tefurumi, Nishio Kazuto

Abstract excerpt

Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase activity. Developmental studies of either drug have failed to show synergistic effects when combined with cytotoxic drugs as the first line treatment in patients with advanced non-small cell lung cancer, but erlotinib has shown survival prolongation when compared with best supportive care...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Asian People
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 17052296
DOI: 10.1111/j.1440-1843.2006.00940.x

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.PMID 17052296Read ↗

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.Semantic proximity Read ↗

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.Semantic proximity Read ↗

[Gefitinib and epidermal growth factor receptor gene mutation].Semantic proximity Read ↗

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study.Semantic proximity Read ↗

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.Semantic proximity Read ↗

Race, gender and mutations in the prediction of anti-EGFR activity.Semantic proximity Read ↗

Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.Semantic proximity Read ↗

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.Semantic proximity Read ↗

Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.